ADA in Medical Technology

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively Assessed in Large Outcomes Trial NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced results from a meta-analysis of ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

Improvements in Systolic Blood Pressure and Triglycerides Also Observed NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) today announced long-term, interim results from the ...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has been selected to present the results from the study, entitled, "Open Label Study to Assess the Safety, Pharma...

Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference

- Oral presentation on the potent blood glucose lowering effect of SGLT2 antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight new metabolic disease targets utilizing antisense SAN FRANCISCO and CARLSBA...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved Glucose Control in Patients Switching from Exenatide Taken Twice a Day SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (N...

Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss

Submitted to FDA for Stand-Alone Therapy in Q1 2008 SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced additional results from a study of patients with type 2 diabetes who were unable t...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is ...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that data featuring its approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline candidates will be presented at the American Diabetes Ass...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improve...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from an investigational study released at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that initial combination therapy with Januvia(TM) (sitagliptin) and metformin demonstrated significant improvement in markers of...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

- ARI-2243 is an highly potent DPP-4 inhibitor, possessing Ki of 27 pM BOSTON, June 25, 2007 /PRNewswire/ -- Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, announced today the results of its potent, smart DPP-4 inhibitor, ARI-2243, presented at the 67th s...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

...ar, known as hypoglycemia. "Despite a range of available diabetes therapies, over half of patients with type 2 diabetes are unable to achieve the ada target blood sugar goal," said the study's lead investigator, Julio Rosenstock, MD of the Dallas Diabetes and Endocrine Center at Medical City and cli...

New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

... - Study Presented at 69th Annual ada Scientific Sessions Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and Apidra(R) - NEW ORLEANS, June 6 /PRNewswire-First...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

...a fragment of immunoglobulin G4 that is believed to increase the duration of its pharmacological effect. Based on this study presented at this year's ada meeting, LY2189265 is believed to reduce blood sugar in patients with type 2 diabetes by enhancing glucose-dependent insulin secretion from the pancre...

Boehringer Ingelheim Unveils Diabetes Pipeline

...living with the disease. Boehringer Ingelheim is inspired to make a difference in diabetes care." Results from the Phase II study presented at ada show that 1, 5 and 10 mg doses of linagliptin achieved clinically relevant and statistically significant reductions in HbA1c, a measure of blood sug...

Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

...cross the continuum of care, experts from AACE and ada were invited to develop an updated consensus state...ng hospital discharge," said Dr. Mary Korytkowski, ada Chair of the Inpatient Glycemic Control Consensus ... About the American Diabetes Association ( ada ) The American Diabetes Association is leading...

Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients

...ol was good (average glucose 144 mg/dl). The ada and AACE caution against letting this study swing ...hospital settings. "Since 2003, AACE and the ada have worked together to provide recommendations fo...rol efficiently and safely," Dr. Mary Korytkowski, ada Chair of Inpatient Glycemic Control Task Force sai...

Worldwide Cost Estimate for Alzheimer's and Dementia Is US$315.4 Billion

... The Alzheimer's Disease Association (ADA) was formed in 1990 as a result of growing concern for the needs of people with dementia and their families. ada is a voluntary welfare organization and is made up of caregivers, professionals and all who are interested in dementia. In addition to groundbreaking ...

February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus

... over time is the glycoslyated hemoglobin A1C test. This blood test, given by a physician, reflects average blood sugar control over three months. The ada recommends maintaining the A1C level at less than 7 percent. New research has indicated that intensive measures required to get below 7 percent might ...

Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes

...ith liraglutide who had not been previously treated with diabetes medications achieved an average reduction in blood sugar that brought them below the ada target for HbA1c of 7%. "This study showed that when used as initial drug treatment for type 2 diabetes, once-daily liraglutide not only statistical...

Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin

... Results from a 24-week multi-center, randomized, open-label study presented at ada 2008 SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced data showing that the use of meal...

Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)

...s with type 2 diabetes who had either established cardiovascular disease or additional CV risk factors, was presented at a press conference during the ada Scientific Sessions and published simultaneously in the New England Journal of Medicine. The study had a mean follow-up of 3.5 years. In total, 7,623 ...

Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

...re presented in full at the American Diabetes Association's 68th Scientific Sessions in San Francisco as a late breaking abstract. The poster from the ada presentation is available on Halozyme's website (http://www.halozyme.com ) About Halozyme Therapeutics, Inc. Halozyme is a biopharmaceutical comp...

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting

...ddress the actual nerve damage. These data demonstrate that SB-509 may have a neuroprotective and a neuroregenerative effect." The data presented at ada were collected from subjects with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509 (SB-509-401). Subject...

Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies

...asure of an individual's average blood sugar over a three-month period. The ada has recommended a target HbA1c level of <7 percent. ada guidelines recommend clinical intervention for HbA1c >8 percent and to be c...

Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control

...f patients from the lifestyle management arm were able to achieve the recommended target levels. In an effort to help guide treatment decisions, the ada and European Association for the Study of Diabetes (EASD) developed a Consensus Algorithm for Type 2 Diabetes that calls for healthcare providers and ...

Continued Funding to Help Advance 'Exciting Moment' in Diabetes Research

...diabetes and to a lesser extent obesity," commented Cathy Bernstein, Chair, ada Research Foundation. "The novel genes identified by this approach were comp...s for building and expanding on these successes," commented Scott Campbell, ada Vice President of Research. "These newly discovered genes provide leads tha...

Drug Combo Could Lower Diabetes Complications and Costs

...ropriate testing and subsequent medical care." The prevalence of diabetes has risen rapidly over the past several decades. New guidelines from the ada recommend screening for diabetes among adults who are overweight or obese or who have one or more risk factors for diabetes before the age of 45. For ...

Reduced Lung Capacity Accelerates With Diabetes

... Makers of Inhaled Insulin Should Take Note, Researchers Say Also: ACC and ada Release New Consensus Statement on Controlling Cardiometabolic Risk ALEXANDRIA, Va., March 27 /PRNewswire-USNewswire/ -- People who have diabetes ...

Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study

...n the study, the Medifast Program outperformed the ada recommended diet in weight loss, adherence and bio...mes. These findings suggest a re-evaluation of the ada recommendation, which currently does not promote p...rol in people with type 2 diabetes to the standard ada recommended dietary guidelines. The study enlisted...

Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes

... glucose levels and low density lipoprotein cholesterol levels (LDL-C). The ada estimates that 20.8 million people in the United States have diabetes with ...face significantly higher risk of developing cardiovascular disease.(3) The ada recommends that patients with type 2 diabetes target an A1C level of <7%.(4...

Help! I'm Sick. How Do I Handle My Diabetes?

...t the battle your body's stress hormones are fighting. -- Nourish a cold - Even if you have lost your appetite, it is important to try to eat. The ada recommends 15 grams of carbohydrates every hour or so. -- Stay hydrated - If you are vomiting or have diarrhea, or have a fever, try to drink a cu...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

...t infections can develop in the skin, muscle, or bones of the foot as a result of nerve damage and poor circulation associated with diabetes. A recent ada study approximates that as many as 9% of Americans with diabetes will develop a diabetic foot infection, and that those who do develop such an infecti...

Diabetes Linked to Higher Parkinson's Risk

... tool in the prevention of diabetes in the severely obese patient." Note: ada clinical practice guidelines recommend that bariatric surgery may be consid...tes.org or call 1-800-DIABETES (1-800-342-2383). Contact: Rachel Morgan, ada (703) 549-1500 ext. 2290 CONTACT: Rachel Morgan of the ADA, +1-703-549-...

Nasulin Interim Results to Be Presented at American Diabetes Association Scientific Sessions

...e largest private endocrine clinic in the United States with over 70,000 active patients, eight board certified endocrinologists, seven NPs/PAs and an ada recognized diabetes education program. The research arm, dgd Research Associates, Inc., has a staff of over 250 employees and has conducted over 1,500...

Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine

... a separate clinical study with the Diamyd vaccine in 160 patients with autoimmune type 2 diabetes (LADA) are also planned to be presented at the same ada Convention. Initiation of Phase III Clinical Trials Diamyd plans to initiate phase III studies in newly onset type 1 diabetics later this year. The...

Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions

...e largest private endocrine clinic in the United States with over 70,000 active patients, eight board certified endocrinologists, seven NPs/PAs and an ada recognized diabetes education program. The research arm, dgd Research Associates, Inc., has a staff of over 250 employees and has conducted over 1,500...

Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard Researcher

...tudy, which will be published in the May 31 issue of The New England Journal of Medicine. Enns is the lead author of the study, and Hopkins researcher ada Hamosh, MD, is the senior author. Urea cycle disorders affect about one in every 8,200 people, but the diagnosis is often missed or delayed. The ...

Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting

...th Annual American Diabetes Association (ADA) Scientific Sessions, to be held in Chicago, June 22 through June 26. Biodel's oral presentation at the ada will take place on June 22 from 4:15 - 6:15pm CST, a summary of which will be available on Biodel's website. Following the presentation, the Company w...